Creating Humabody™
fully-human antibody
fragment therapeutics

Crescendo Biologics is developing innovative new medicines based on its best-in-class antibody fragment technology.

Crescendo’s Humabody™ approach is being applied to its in-house pipeline targeting dermatology and oncology indications and through strategic partnerships.

Made possible by the proprietary Crescendo Mouse, Humabodies™ bring the full power of transgenic mouse technology to antibody fragment development by providing in vivo maturation and fully-human sequence.

 

News & Events
Dec 16, 2014
Crescendo Biologics’ Receives Further Investment from Astellas...
Oct 3, 2014
Crescendo Biologics Recognised at OBN Annual Awards Dinner
© 2014 Crescendo Biologics